The characteristics of the 247 patients with AML receiving preemptive IFN-α therapy following allo-HSCT are summarized in Table 1 and Figure 2, and information about human leukocyte antigen (HLA) disparity for haploidentical donor (HID) HSCT is shown in Supplementary Table 1. The gene discussed is IFNA2; the disease is acute myeloid leukemia.